MedTrace Logo

CART Therapy in GUCY2C-positive Digestive Tract Tumors

NCT04652219 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2023-07-17

No results posted yet for this study

Summary

Ict-gc is an open, single-center study to evaluate the safety and efficacy of CAR-T-targeted therapy in patients with advanced gastrointestinal tumors.

Conditions

  • Malignant Neoplasms of Digestive Organs

Interventions

BIOLOGICAL

gucy2c cart cells

Patients with advanced malignant gastrointestinal tumors were injected with CART cells

Sponsors & Collaborators

  • Innovative Cellular Therapeutics Co., Ltd.

    collaborator OTHER

  • Weijia Fang, MD

    lead OTHER

Principal Investigators

  • Weijia Fang · First Affiliated Hospital,Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-10
Primary Completion
2021-10-09
Completion
2021-10-09

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04652219 on ClinicalTrials.gov